EGFR and colorectal carcinoma: Cetuximab was the first FDA‐approved anti‐EGFR antibody for CRC therapy, and has been used in combination with standard chemotherapy or radiotherapy in locally advanced, metastatic, and recurrent CRC.[22, 23] However, cetuximab resistance remains a major clinical challenge.